Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Replimune Group

Tracked across 9 events · 614 articles · First seen Jul 25, 2025 · Last active Sep 22, 2026

Sentiment
-7
Attention
7
Events
9
Relationships
8
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 20
Regulatory
Impact: The FDA's acceptance of the BLA resubmission for RP1 is a significant step towards potential accelerated approval, which could lead to increased revenue and market presence for Replimune Group. However, the stock price was down in pre-market trading, indicating some investor caution.
Jun 26, 2026 · 8 articles
2 -85
Regulatory
Multiple investor-rights law firms have filed securities fraud class actions against Replimune Group (NASDAQ: REPL) and certain of its officers, alleging violations of federal securities laws during the class period of October 20, 2025 to…
Impact: Central defendant in the securities class actions and issuer of the rejected BLA; its shares reportedly collapsed from $4.76 to $1.70 in April 2026 and it faces ongoing litigation and regulatory setbacks.
Jul 29, 2026 · 139 articles
2 -70
Regulatory
Pomerantz LLP announced a securities class action lawsuit against Replimune Group on behalf of investors who acquired Replimune securities during the Class Period. The suit alleges that Replimune and certain officers and/or directors engaged in…
Impact: Replimune Group is the target of the securities class action and the company whose BLA was rejected by the United States — Food and Drug Administration, triggering a roughly 84 percent two-day share price collapse. The litigation and regulatory setback severely damage its near-term prospects and investor confidence.
Sep 03, 2026 · 6 articles
6 -20
Domestic
Impact: Replimune Group>>> experienced rejection of its melanoma therapy by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership, leading to public criticism and contributing to the pressure for his ouster.
May 08, 2026 · 114 articles
4 30
Regulatory
Impact: Replimune Group received accelerated approval for its melanoma drug after a regulatory battle, benefiting from FDA decisions.
Aug 25, 2026 · 6 articles
6 -10
Domestic
Impact: Replimune Group, a biotech, had disagreements with the FDA under Makary. Overton's nomination may affect rare-disease drug approvals.
Aug 19, 2026 · 101 articles
7 60
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: Replimune recently received FDA approval for its melanoma therapy Tudriqev. The success of the Moderna-Merck vaccine may increase competition but also validates the broader field of cancer immunotherapy.
Aug 19, 2026 · 126 articles
7 10
Regulatory
Impact: Replimune Group was mentioned in context of FDA scrutiny under Makary, but is not directly affected by this approval.
Aug 05, 2026 · 105 articles
2 0
Business
Impact: Dieter Weinand currently serves on the board of Replimune Group, and will reduce his board seats to focus on his role at Evotec.
Apr 07, 2026 · 9 articles
70 Replimune Group conceded randomized trial preferredReplimune Securities Fraud...
+ 2 more actions View on Dashboard
ERGEN INTELLIGENCE
Track Replimune Group live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.